Continuous subcutaneous insulin infusion in type 1 diabetes: Is beneficial in selected patients and should be more widely available

BMJ

Volumn 322, Issue 7297, 2001, Pages 1262-1263

  Pickup, John ^a   Keen, Harry ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

BLOOD GLUCOSE MONITORING; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIC COMA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; KETOACIDOSIS; PRIORITY JOURNAL; UNITED KINGDOM;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIA; INSULIN INFUSION SYSTEMS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0035954117     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.322.7297.1262     Document Type: Editorial

References (12)

1. Pickup JC, Keen H, Parsons JA, Alberti KGMM. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. BMJ 1978; 1: 204–207.
2. Locke DR, Rigg LA. Hypoglycemic coma associated with subcutaneous insulin infusion by portable pump. Diabetes Care 1981; 4: 389–391.
3. Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 361–376.
4. Chantelau E, Spraul M, Mühlhauser I, Gause R, Berger M. Long-term safety, efficacy and side effects of continuous subcutaneous insulin infusion treatment for type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 1989; 32: 421–426.
5. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 1996; 19: 324–327.
6. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999; 22: 1784–1799.
7. Bending JJ, Pickup JC, Keen H. Frequency of diabetic ketoacidosis and hypoglycemic coma during treatment with continuous subcutaneous insulin infusion. Am J Med 1985; 79: 685–691.
8. Dahl-Jørgensen K, Bringhman-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smelund E, et al. Effect of near-normoglycaemia for two years on the progression of early diabetic retinopathy: the Oslo Study. BMJ 1986; 293: 1195–1199.
9. 1c and blood glucose stability in IDDM patients with lispro insulin analogue in external pumps. Diabetes Care 1998; 21: 977–981.
10. Mecklenburg RS, Benson EA, Benson JW, Fredlund PN, Guinn T, Metz RJ, et al. Acute complications associated with insulin pump therapy. Report of experience with 161 patients. JAMA 1984; 252: 3265–3269.
11. Koivisto VA, Yki-Järvinen H, Helve E, Karonen S-L, Pelkonen R. Pathogenesis of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 1986; 35: 78–82.
12. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42: 1151–1167.